An open-label study to evaluate the optimal dose of Xeloda [capecitabine] when combined with Eloxatin [oxaliplatin] and pre-operative pelvic irradiation in patients with locally advanced rectal cancer.

An open-label study to evaluate the optimal dose of Xeloda [capecitabine] when combined with Eloxatin [oxaliplatin] and pre-operative pelvic irradiation in patients with locally advanced rectal cancer.